on Evotec AG (NASDAQ:EVTCY)
Evotec Joins NURTuRE-AKI Consortium for Acute Kidney Injury Research
Evotec SE has announced its participation in the NURTuRE-AKI consortium, a research initiative led by Kidney Research UK. This venture aims to enhance the understanding of acute kidney injury (AKI) through a multi-omics approach, focusing on patients from specific cohorts, including pediatric and post-cardiac surgery AKI cases.
The study involves longitudinal data and biological samples collection, fostering the discovery of innovative treatments based on molecular insights. Blood, urine, and research biopsy samples will undergo comprehensive analyses, contributing to Evotec’s Molecular Patient Database.
This collaboration seeks to uncover novel therapeutic targets and biomarkers, potentially advancing the treatment landscape for AKI. Evotec is actively seeking partners to support this endeavor, emphasizing its commitment to kidney disease research and drug development.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Evotec AG news